Angiotensin Converting Enzyme 2 News and Research

RSS

Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections

Intranasal administration of neomycin sulfate in murine models shows promise as a prophylactic and therapeutic agent against respiratory viruses like influenza A and SARS-CoV-2 by inducing interferon-stimulated gene (ISG) expression, independent of microbiota and interferon activation.

24 Apr 2024

New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses

Researchers at Georgia Tech and the University of Wisconsin have created a broad-spectrum vaccine capable of defending against various SARS-CoV-2 variants and related bat coronaviruses.

17 Apr 2024

Vitamin D deficiency persists despite easy access, review suggests need for tailored supplements

Researchers in a study published in the journal Nutrients delve into the pervasive issue of vitamin D deficiency and its link to various health conditions, advocating for precision nutrition and personalized supplementation to enhance vitamin D intake and effectiveness.

17 Apr 2024

Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity

Researchers identified how SARS-CoV-2 targets and manipulates specific lung cells, using innovative techniques to trace the virus's impact on the cells' gene expression, revealing insights into early COVID-19 pathogenesis.

14 Apr 2024

Beta-blockers show no benefit for heart attack patients with normal heart function

The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared to no beta-blocker treatment.

8 Apr 2024

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Study: Empagliflozin shows mixed results in heart attack patients

Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Study introduces Reverse Vaccine Development as a strategic approach to identify correlates of protection early in vaccine development against antimicrobial-resistant pathogens, aiming to mitigate risks such as significant phase-III clinical trial failures.

7 Apr 2024

Antibody discovery could explain mysteries about COVID-19 and long COVID

UVA Health researchers have discovered a potential explanation for some of the most perplexing mysteries of COVID-19 and long COVID.

28 Mar 2024

Heart at risk from ARDS: Inflammatory responses fuel cardiovascular complications

Research highlights the inflammatory impacts of ARDS on the heart, underscoring the role of immune responses in cardiovascular complications from viral infections, including COVID-19, and emphasizes the potential of TNF-α neutralizing therapy to mitigate these effects.

24 Mar 2024

Study suggests treating anxiety and depression significantly reduces ER visits and rehospitalizations among heart disease patients

A new study looks at this area in order to provide evidence for key recommendations in the treatment of such patients.

22 Mar 2024

Severity of current SARS-CoV-2 variants is not linked to the number of mutations

New research from UNC Charlotte's Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two most prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to previous variants.

19 Mar 2024

Understanding long COVID: A call for better diagnosis and treatment

A recent review in Nature Reviews Microbiology summarizes the complex mechanisms, significant impacts, and the urgent need for enhanced diagnostics and treatments for long COVID, affecting over 65 million people globally with diverse, debilitating symptoms and systemic health issues.

7 Mar 2024